Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy

J HIV Ther. 2010 Mar;15(1):15-7.
No abstract available

MeSH terms

  • AIDS Vaccines / therapeutic use
  • Anti-HIV Agents / therapeutic use
  • Clinical Trials as Topic
  • HIV Infections / therapy*
  • Humans
  • Immunotherapy
  • Interleukin-2 / analogs & derivatives
  • Interleukin-2 / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Treatment Outcome

Substances

  • AIDS Vaccines
  • Anti-HIV Agents
  • Interleukin-2
  • Recombinant Proteins
  • aldesleukin